LUMINESPIB

Drug Novartis Pharmaceuticals Corporation
Total Payments
$217,166
Transactions
13
Doctors
1
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2019 $22,800 2 0
2018 $13,004 1 0
2017 $181,362 10 1

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $217,166 13 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
AUY922 IN NSCLC PATIENTS WITH EXON 20 INSERTION MUTATIONS IN EGFR Novartis Pharmaceuticals Corporation $156,931 0
AN OPEN LABEL SINGLE ARM MULTI CENTER PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AUY922 IN COMBINATION WITH TRASTUZUMAB STANDARD THERAPY AS SECOND LINE TREATMENT IN PATIENTS WITH HER2 POSITIVE ADVANCED GASTRIC CANCER Novartis Pharmaceuticals Corporation $27,986 0
A RANDOMIZED PHASE II STUDY OF AUY922 IN EGFRM PLUS NSCLC Novartis Pharmaceuticals Corporation $18,385 0
PHASE IB DOSE ESCALATION TRIAL OF PEMETREXED AND AUY922 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC NON SQUAMOUS NON SMALL CELL LUNG CANCER Novartis Pharmaceuticals Corporation $5,600 0
A PHASE II MULTI CENTER OPEN LABEL STUDY OF AUY922 ADMINISTERED IV ON A ONCE WEEKLY SCHEDULE IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST TWO LINES OF PRIOR CHEMOTHERAPY Novartis Pharmaceuticals Corporation $2,976 0
A PHASE IB AND OR II MULTI CENTER OPEN LABEL STUDY TO EVALUATE THE EFFICACY OF AUY922 IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2 POSITIVE BREAST CANCER THAT HAS PROGRESSED AFTER OR DURING AT LEAST ONE TRASTUZUMAB CONTAINING REGIMEN Novartis Pharmaceuticals Corporation $2,545 0
A PHASE II OPEN LABEL STUDY OF AUY922 IN ALK REARRANGED NON SMALL CELL LUNG CANCER WITH ACQUIRED RESISTANCE TO CRIZOTINIB Novartis Pharmaceuticals Corporation $1,750 0
RESEARCH RELATED PUBLICATION SUPPORT NOVARTIS PHARMACEUTICALS CORPORATION $992.11 1

Top Doctors Receiving Payments for LUMINESPIB

Doctor Specialty Location Total Records
Unknown — Santa Monica, CA $216,174 12
, MD Internal Medicine Boston, MA $992.11 1

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $217,166
  • Total Doctors 1
  • Transactions 13

About LUMINESPIB

LUMINESPIB is a drug associated with $217,166 in payments to 1 healthcare providers, recorded across 13 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.

Payment data is available from 2017 to 2019. In 2019, $22,800 was paid across 2 transactions to 0 doctors.

The most common payment nature for LUMINESPIB is "Unspecified" ($217,166, 100.0% of total).

LUMINESPIB is associated with 8 research studies, including "AUY922 IN NSCLC PATIENTS WITH EXON 20 INSERTION MUTATIONS IN EGFR" ($156,931).